health · HHS-NIH11
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
National Institutes of Health · PAR-26-120
Expected Awards
10
Deadline
TBD
GRANTQUICK SUMMARYPlain-English Overview
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional). National Institutes of Health. Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and... ~10 awards expected.
Who Should Apply
For-profit organizations, County governments, Special district governments, Other Native American Tribal Organizations, City/township governments (+10 more)
Who Should NOT Apply
Organizations not matching the eligible applicant types listed above
Key Requirements (Plain English)
- •Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U
💡 GrantQuick Tip
Focus your proposal on clear outcomes, alignment with agency priorities, and demonstrate organizational capacity.
Competitiveness: High — limited number of awards
What This Grant Funds
Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying patients at high risk of PDAC (because of genetic factors, family history and/or the presence of precursor lesions) who could be candidates for early intervention.
The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; develop molecular- and/or imaging-based markers of pancreatic cysts and determine which lesions are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens, and data within the Consortium.
The other scientific component of the PCDC will be the Management and Data Coordination Unit, which will provide support toward study design, protocol development, statistical analysis, coordination, harmonization, data management and stewardship for the trans-PCDC collaborative projects, including biorepository building effort.
Who Can Apply
Eligible Applicant Types
Funding Details
- Expected Number of Awards
- 10
- Cost Sharing Required?
- No
- Funding Instrument
- cooperative_agreement
Key Dates
Agency Contact
DCP CBB Please contact via e-mail
ncipcdc@nih.govReady to apply?
View the full NOFO and submit your application on Grants.gov